UroGen Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell UroGen Pharma and other ETFs, options, and stocks.

About URGN

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. 

CEO
Elizabeth Barrett
CEOElizabeth Barrett
Employees
291
Employees291
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
2004
Founded2004
Employees
291
Employees291

URGN Key Statistics

Market cap
1.71B
Market cap1.71B
Price-Earnings ratio
-12.76
Price-Earnings ratio-12.76
Dividend yield
Dividend yield
Average volume
644.39K
Average volume644.39K
High today
$35.56
High today$35.56
Low today
$34.19
Low today$34.19
Open price
$34.23
Open price$34.23
Volume
465.06K
Volume465.06K
52 Week high
$35.56
52 Week high$35.56
52 Week low
$12.73
52 Week low$12.73

Stock Snapshot

The current UroGen Pharma(URGN) stock price is $35.15, with a market capitalization of 1.71B. The stock trades at a price-to-earnings (P/E) ratio of -12.76.

On 2026-06-23, UroGen Pharma(URGN) stock moved within a range of $34.19 to $35.56. With shares now at $35.15, the stock is trading +2.8% above its intraday low and -1.2% below the session's peak.

Trading volume for UroGen Pharma(URGN) stock has reached 465.06K, versus its average volume of 644.39K.

The stock's 52-week range extends from a low of $12.73 to a high of $35.56.

The stock's 52-week range extends from a low of $12.73 to a high of $35.56.

URGN News

TipRanks 6h
UroGen Shareholders Approve Governance, Compensation and Auditor Changes

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Simply Wall St 6d
Why UroGen Pharma Is Up 17.2% After Teva Patent Settlement And Zusduri Sales Surge - simplywall.st

...

Why UroGen Pharma Is Up 17.2% After Teva Patent Settlement And Zusduri Sales Surge - simplywall.st

Analyst ratings

88%

of 8 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

People also own

Based on the portfolios of people who own URGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.